At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
dinaciclib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating dinaciclib and laboratory biomarker analysis for Refractory Multiple Myeloma. Completed, enrolled 16 participants across 6 sites in 2 countries.
Detailed Summary
This phase II trial is studying how well giving dinaciclib works in treating patients with relapsed or refractory multiple myeloma. Dinaciclib may stop the growth of cancer cells by clocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Multiple Myeloma
CountriesSingapore, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedMar 2010
Primary CompletionDec 2011
Study CompletionDec 2012
TodayJul 2026
First PostedMar 31, 2010
Enrollment StartJul 1, 2009
Primary CompletionDec 1, 2011
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.3 years ago
Interventions
dinaciclibdrug
Given IV
laboratory biomarker analysisother
Correlative studies